Cargando…
DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma
BACKGROUND: Skin cutaneous melanoma (SKCM) is a highly malignant skin tumor. DIRAS2 is considered to be a tumor suppressor gene; however, its function in SKCM has not been explored. METHODS: The Gene Expression Profiling Interactive Analysis (GEPIA) was implemented to investigate the expression of D...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149220/ https://www.ncbi.nlm.nih.gov/pubmed/35651810 http://dx.doi.org/10.3389/fonc.2022.799185 |
_version_ | 1784717160623374336 |
---|---|
author | Xue, Wenli Zhu, Hongbo Liu, Hongye He, Hongxia |
author_facet | Xue, Wenli Zhu, Hongbo Liu, Hongye He, Hongxia |
author_sort | Xue, Wenli |
collection | PubMed |
description | BACKGROUND: Skin cutaneous melanoma (SKCM) is a highly malignant skin tumor. DIRAS2 is considered to be a tumor suppressor gene; however, its function in SKCM has not been explored. METHODS: The Gene Expression Profiling Interactive Analysis (GEPIA) was implemented to investigate the expression of DIRAS2 in SKCM, and plot the survival curve to determine the effect of DIRAS2 on the survival rates of SKCM patients. Then, the correlation between DIRAS2 and tumor immune infiltration was also discussed, and the expression of DIRAS2 and immune infiltration level in SKCM immune cells was determined using TIMER. The top 100 genes most associated with DIRAS2 expression were used for functional enrichment analysis. In order to confirm the anti-cancer effects of DIRAS2 in SKCM in the data analysis, in vitro assays as well as in vivo studies of DIRAS2 on SKCM tumor cell proliferation, migration, invasion, and metastasis were conducted. Western blot and immunofluorescence assay were employed to study the relationship between DIRAS2 and Wnt/β-catenin signaling pathway in SKCM. RESULTS: DIRAS2 expression was shown to be significantly correlated with tumor grade using univariate logistic regression analysis. DIRAS2 was found to be an independent prognostic factor for SKCM in multivariate analysis. Of note, DIRAS2 expression levels were positively correlated with the infiltration levels of B cells, CD4+ T cells, and CD8+ T cells in SKCM. The infiltration of B cells, CD4+ T cells, and CD8+ T cells was positively correlated with the cumulative survival rate of SKCM patients. In vitro experiments suggested that proliferation, migration, invasion, and metastasis of SKCM tumor cells were distinctly enhanced after DIRAS2 knockdown. Furthermore, DIRAS2 depletion promoted melanoma growth and metastasis in vivo. As for the mechanism, silencing DIRAS2 can activate the signal transduction of the Wnt/β-catenin signaling pathway. CONCLUSION: DIRAS2 functions as a tumor suppressor gene in cases of SKCM by inhibiting the Wnt/β-catenin signaling. It is also associated with immune infiltration in SKCM. |
format | Online Article Text |
id | pubmed-9149220 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91492202022-05-31 DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma Xue, Wenli Zhu, Hongbo Liu, Hongye He, Hongxia Front Oncol Oncology BACKGROUND: Skin cutaneous melanoma (SKCM) is a highly malignant skin tumor. DIRAS2 is considered to be a tumor suppressor gene; however, its function in SKCM has not been explored. METHODS: The Gene Expression Profiling Interactive Analysis (GEPIA) was implemented to investigate the expression of DIRAS2 in SKCM, and plot the survival curve to determine the effect of DIRAS2 on the survival rates of SKCM patients. Then, the correlation between DIRAS2 and tumor immune infiltration was also discussed, and the expression of DIRAS2 and immune infiltration level in SKCM immune cells was determined using TIMER. The top 100 genes most associated with DIRAS2 expression were used for functional enrichment analysis. In order to confirm the anti-cancer effects of DIRAS2 in SKCM in the data analysis, in vitro assays as well as in vivo studies of DIRAS2 on SKCM tumor cell proliferation, migration, invasion, and metastasis were conducted. Western blot and immunofluorescence assay were employed to study the relationship between DIRAS2 and Wnt/β-catenin signaling pathway in SKCM. RESULTS: DIRAS2 expression was shown to be significantly correlated with tumor grade using univariate logistic regression analysis. DIRAS2 was found to be an independent prognostic factor for SKCM in multivariate analysis. Of note, DIRAS2 expression levels were positively correlated with the infiltration levels of B cells, CD4+ T cells, and CD8+ T cells in SKCM. The infiltration of B cells, CD4+ T cells, and CD8+ T cells was positively correlated with the cumulative survival rate of SKCM patients. In vitro experiments suggested that proliferation, migration, invasion, and metastasis of SKCM tumor cells were distinctly enhanced after DIRAS2 knockdown. Furthermore, DIRAS2 depletion promoted melanoma growth and metastasis in vivo. As for the mechanism, silencing DIRAS2 can activate the signal transduction of the Wnt/β-catenin signaling pathway. CONCLUSION: DIRAS2 functions as a tumor suppressor gene in cases of SKCM by inhibiting the Wnt/β-catenin signaling. It is also associated with immune infiltration in SKCM. Frontiers Media S.A. 2022-05-16 /pmc/articles/PMC9149220/ /pubmed/35651810 http://dx.doi.org/10.3389/fonc.2022.799185 Text en Copyright © 2022 Xue, Zhu, Liu and He https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Xue, Wenli Zhu, Hongbo Liu, Hongye He, Hongxia DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma |
title | DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma |
title_full | DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma |
title_fullStr | DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma |
title_full_unstemmed | DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma |
title_short | DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma |
title_sort | diras2 is a prognostic biomarker and linked with immune infiltrates in melanoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149220/ https://www.ncbi.nlm.nih.gov/pubmed/35651810 http://dx.doi.org/10.3389/fonc.2022.799185 |
work_keys_str_mv | AT xuewenli diras2isaprognosticbiomarkerandlinkedwithimmuneinfiltratesinmelanoma AT zhuhongbo diras2isaprognosticbiomarkerandlinkedwithimmuneinfiltratesinmelanoma AT liuhongye diras2isaprognosticbiomarkerandlinkedwithimmuneinfiltratesinmelanoma AT hehongxia diras2isaprognosticbiomarkerandlinkedwithimmuneinfiltratesinmelanoma |